纳米载体共载基因与化疗药物用于癌症治疗的研究进展-药学学报.PDF

药学学报 Acta Pharmaceutica Sinica 20 13, 48 (7): 1091 1098 ·1091 · 米载体共载基因与化疗药物用于癌症治疗的研究进展 1 1, 2* 陈伟光 , 王士斌 (华侨大学 1. 化工学院, 2. 生物材料与组织工程研究所, 福建 厦门 361021) 摘要: 随着纳米技术与RNA 干扰 (RNA interference, RNAi) 技术的发展, 纳米载体 (nanocarriers, NCS) 作 为一类新型的基因与药物共载载体在癌症治疗中的应用潜能逐渐彰显, 特别是在多 耐 (multidurg-resistance, MDR) 肿瘤研究领域。NCS 共载基因与化疗药物联合治疗癌症, 相对传统化疗, 该方法可以减少化疗药物的使 用剂量, 增加 物在靶器官的分布量, 以达到减 毒副作用及提高疗效的目的。因此在未来癌症治疗中, 特别在 MDR 的临床治疗中, NCS 共载基因与化疗 物联合治疗递送体系将产生重要作用。 关键词: 纳米载体; 基因; 化疗药物; 共载; 肿瘤治疗 中图分类号: R943 文献标识码: A 文章编号: 0513-4870 (20 13) 07- 1091-08 Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for cancer therapy 1 1, 2* CHEN Wei-guang , WANG Shi-bin (1. College of Chemical Engineering, 2. Insititute of Biomaterials and Tissue Engineering, Huaqiao University, X iamen 361021, China ) Abstract : Current trends in nanotechnology and RNA interference technology have made the application of nanocarriers (NCS) as a novel gene and drug delivery systems very promising for the field of multidrug resistance (MDR) cancer treatment. Co-delivery of gene and chemotherapy drugs with NC S has a good synergistic effect compared with the traditional chemotherapy which can increase the amount of the drug distribution in target organ in order to reduce the toxic side effects thereby enhancing efficacy. Therefore, the advent of co-delive